Clinical trials: Obesity & Overweight
Overweight and/or Obesity, Healthy Participants
A Study to Learn How Different Forms of the Study Medicine Called Berobenatide is Taken up Into the Blood in Adults With Overweight or Obesity
This is a single dose study to learn how safe and effective the study medicine is using different delivery systems for adults with overweight or obesity. Overweight or obesity means having more body fat than what is healthy.
- Trial name
- NCT07876531
- Testing
- Berobenatide
- Where
- United States
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity & Overweight
WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults
This research study is studying WeDosify, an interactive web-based Clinical Decision Support tool that assists healthcare professionals in managing adults with excess weight or obesity using a Glucagon-like peptide-1 (GLP-1) drug…
- Trial name
- NCT07216651
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Closed Loop Medicine
Obesity, Behavior, Health
Evaluation of Brain Activity Changes After a Behavior Change Weight Loss Intervention
The aim of this study is to compare brain changes in individuals with overweight or obesity enrolled in either the Noom Healthy Weight program or a matched control.
- Conditions
- Obesity, Behavior, Health, Weight Loss
- Trial name
- NCT04522245
- Testing
- Noom Healthy Weight; mobile behavior change program for weight loss., Matched Control
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Noom Inc.
Obesity or Overweight
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with…
- Trial name
- Enith1 (NCT07351045)
- Testing
- Enicepatide
- Where
- 209 sites in United States, Argentina and 19 more
- Volunteers
- 2,000 people
- Sponsor
- Hoffmann-La Roche
Overweight and Obesity, Health Behavior
Location-based Smartphone Technology to Guide College Students Healthy Choices Ph II
College students are in a newly independent phase of life; many of whom encounter unhealthy dietary decision- making, barriers to physical activity, and poor sleep behaviors.
- Conditions
- Overweight and Obesity, Health Behavior, Sleep Deprivation
- Trial name
- NCT02996864
- Testing
- Healthy Detours App, Fat Secret App
- Where
- 2 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Klein Buendel, Inc.
Obesity
A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants
This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study: To evaluate the efficacy of different dose levels of CX11 tablets in body weight reduction as compared to placebo.
- Trial name
- NCT07011797
- Testing
- CX11
- Where
- 17 sites in United States
- Volunteers
- 250 people
- Sponsor
- Corxel Pharmaceuticals
Obesity
AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week.
- Trial name
- AMAZE 12 (NCT07503210)
- Testing
- NNC0487-0111
- Where
- 72 sites in United States, Argentina and 10 more
- Volunteers
- 606 people
- Sponsor
- Novo Nordisk A/S
Obesity, COPD
Evaluation of Muscle Activation Efficiency in Challenging Subjects
The purpose of this study is to determine whether muscle activation can be accomplished more effectively and comfortably in challenging subjects using novel configurations of an activation device.
- Trial name
- NCT01811446
- Testing
- Muscle Activation with Niveus and Intelect Devices
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Niveus Medical, Inc.
Diabetes type2, Obesity
The RESET System Pivotal Clinical Trial (Protocol Revision K)
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the RESET System for Glycemic Improvement in Patients with Inadequately Controlled Type 2 Diabetes and Obesity, the STEP-1 Study.
- Trial name
- STEP-1 (NCT04101669)
- Testing
- RESET Liner
- Where
- 27 sites in United States
- Volunteers
- 264 people
- Sponsor
- Morphic Medical Inc.
Weight Loss, Obesity
Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid Condition
This is a Phase 2 randomized, double-blind, placebo-controlled, parallel arm study of NA-931 in adults who are obese (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition.
- Conditions
- Weight Loss, Obesity, Body Weight, Body Weight Changes
- Trial name
- NCT06564753
- Testing
- NA-931, dose 1, daily and orally, NA-931, dose2, daily and orally, NA-931 dose 3, daily and orally
- Where
- 5 sites in Australia
- Volunteers
- 126 people
- Sponsor
- Biomed Industries, Inc.
Obesity, Overweight
A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
The main purpose of this study, performed under Master Protocol J4M-MC-PWMP (NCT06672549), is to evaluate the efficacy, safety, and pharmacokinetics of orforglipron once daily oral versus Placebo in adolescent participants with…
- Trial name
- NCT06672939
- Testing
- Orforglipron
- Where
- 34 sites in United States, Israel and 4 more
- Volunteers
- 150 people
- Sponsor
- Eli Lilly and Company
Obesity
Study Examing The Effect Of Omeprazole On Safety, Tolerability And How The Body Processes An Experimental Drug
Experiment in the test tube indicated that CP-945,598 becomes less soluble with increase of pH (less acidity). Changes in stomach acid levels may affect the solubility of CP-945,598, therefore, alters its availability in the…
- Trial name
- NCT00644839
- Testing
- CP-945,598
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Pfizer
Roux-en-Y Gastric Bypass, Obesity
Assessing the Safety and Performance of the easyEndoTM Universal Linear Cutting Stapler in Laparoscopic Gastric Bypass Surgery
The purpose of this observational registry is to evaluate the safety and performance of the easyEndoTM Universal Linear Cutting Stapler and reloads from Ezisurg Medical used in laparoscopic RYGB surgery to create anastomoses.
- Trial name
- NCT03968757
- Testing
- easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)
- Where
- Belgium
- Volunteers
- 150 people
- Sponsor
- Duomed
Overweight, Obesity
A Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on How the Medicine Zenagamtide is Taken up by the Body of Participants With Overweight or Obesity
The purpose of this clinical study is to test how taking zenagamtide tablets with different meal/water variations affects how much zenagamtide enters the bloodstream in people who have overweight or obesity.
- Trial name
- NCT07815067
- Testing
- Zenagamtide injection, Zenagamtide tablet
- Where
- Germany
- Volunteers
- 320 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a…
- Trial name
- NCT06603571
- Testing
- LY3841136, Tirzepatide
- Where
- 52 sites in United States, Argentina
- Volunteers
- 367 people
- Sponsor
- Eli Lilly and Company
Obesity
Study of Five Different Methods Of Delivering A Lifestyle Modification Program for Weight Loss
The aim of the study was to compare 5 methods of delivering a weight loss lifestyle modification program to obese patients on a background of sibutramine.
- Trial name
- NCT00471172
- Testing
- Face-to-face counseling by a dietitian (months 1-3: weekly, months 4-6: every other week), Face-to-face counseling by a dietitian (monthly), Counseling by a dietitian via telephone (months 1-3: weekly, months 4-6: every other week)
- Where
- 12 sites in United States
- Volunteers
- 350 people
- Sponsor
- Pfizer
Obesity, Overweight and/or Obesity
A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity
The purpose of this study is to learn about the safety and effectiveness of berobenatide in adults with overweight or obesity who have already lost weight while taking semaglutide or tirzepatide.
- Conditions
- Obesity, Overweight and/or Obesity, Overweight, Treatment Of Obesity
- Trial name
- NCT07845500
- Testing
- Semaglutide, Berobenatide, Tirzepatide
- Where
- 16 sites in United States
- Volunteers
- 660 people
- Sponsor
- Pfizer
Obesity
A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943
The main purpose of the study is to look at the effect of the study drug compared to placebo on calorie intake, energy metabolism, and appetite. The study will last up to 6 months and may include up to 20 visits.
- Trial name
- NCT06313528
- Testing
- LY3437943
- Where
- 3 sites in United States
- Volunteers
- 85 people
- Sponsor
- Eli Lilly and Company
Overweight and/or Obesity
Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants
VX-201-101 is a first-in-human Phase 1 clinical study evaluating VX-201, a needle-free microneedle (MN) array patch (MAP) that delivers semaglutide through the skin as an alternative to subcutaneous (SC) injection.
- Trial name
- NCT07673900
- Testing
- VX-201, semaglutide SC
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Terrestrial Bio, Inc.
Diabetes Mellitus Type 2
Multiple Dose Safety Tolerability, Pharmacokinetics And Midazolam Interaction In Healthy Overweight And Obese Subjects
This study is designed to assess the safety, tolerability and pharmacokinetics of multiple oral 200-mg doses of PF-05175157 administered twice daily for 14 days in healthy overweight and obese subjects.
- Trial name
- NCT01807377
- Testing
- PF-05175157, Midazolam
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.